FDA Warns Supplement Makers Over Unsupported Claims Related to Stress Relief

FDA Sends Warning Letters to Supplement Companies for Anxiety and Stress Claims

The FDA has notified multiple dietary supplement companies that claims promising to reduce stress, relieve anxiety, support calm or treat related symptoms count as disease claims. Under the Federal Food, Drug, and Cosmetic Act, those statements reclassify the products as unapproved new drugs. The agency has not reviewed such products for safety or efficacy through the drug approval process. Its guidance documents spell out the exact line between permitted language and prohibited statements.

Dietary supplements fall under different rules than drugs. The FDA does not approve them before they reach store shelves. Manufacturers remain responsible for the accuracy of their labels and marketing. [3]

Permitted Claims Versus Prohibited Ones

The FDA permits structure or function claims without prior review. These statements describe effects on normal body structures or functions, such as helping maintain healthy cortisol levels, when the claims stay truthful and carry a mandatory disclaimer. Disease claims go further. They suggest a product can diagnose, mitigate, treat, cure or prevent a disease or related condition. [2]

References to relieving anxiety, reducing stress disorders or addressing clinical symptoms cross into that category. Such language turns a supplement into an unapproved drug under federal law. [1]

Evidence Standards for Mental Health Claims

Structure or function claims require competent and reliable scientific evidence. Disease claims linked to mental health demand full clinical trials plus formal FDA approval as a new drug. Many ingredients sold for stress support lack the data needed for strong therapeutic statements. [2]

The agency places the burden on companies to substantiate whatever they say. It does not vet supplements in advance for claim accuracy. [3]

How the FDA Responds to Violations

Warning letters inform firms of specific labeling or marketing problems. The letters request corrective steps within a defined period. Continued violations can trigger product seizures, court injunctions or criminal penalties. [3]

Recent letters targeted phrases such as “reduce stress” or “relieve anxiety” on labels and websites. Those actions restated the legal boundary. [1]

What this means

The letters draw a clear line between wellness-oriented structure or function language and medical claims that require drug-level evidence. They signal that mental health descriptors trigger stricter regulatory standards. Manufacturers now face explicit expectations around label revisions to prevent products from being reclassified.

Key takeaways

• Claims to mitigate, treat, or prevent anxiety, stress disorders, or related symptoms cause a product to be classified as an unapproved drug. [1]
• Structure/function claims are allowed without pre-approval if truthful, free of disease implications, and paired with the required disclaimer. [2]
• The FDA does not pre-approve dietary supplements but holds companies responsible for truthful labeling and substantiation. [3]
• Warning letters notify firms of violations and can lead to seizures, injunctions, or penalties for noncompliance. [3]
• Scientific evidence on many botanical or nutrient ingredients marketed for stress remains limited and often inconclusive for therapeutic statements. [2]

Limitations

Specific warning letters address individual products and companies. Current enforcement details appear in the latest FDA announcements. This content addresses regulatory compliance only and does not evaluate the safety or efficacy of any particular dietary ingredient. Scientific evidence on many botanical or nutrient ingredients for stress modulation remains limited and often inconclusive for strong therapeutic claims.

FAQ

What is the difference between allowed structure/function claims and illegal disease claims on dietary supplements?
Structure/function claims describe effects on normal body processes and require substantiation without prior FDA approval. Disease claims imply the ability to treat or prevent conditions such as anxiety or stress disorders and classify the product as an unapproved drug. [1][2]

What evidence standard must companies meet to make mental health-related claims?
Structure/function claims need competent and reliable scientific evidence plus a mandatory disclaimer. Disease claims for mental health symptoms demand clinical trial data and formal FDA approval as a new drug. [2]

How does the FDA enforce rules on dietary supplement labeling and marketing?
The agency issues warning letters that identify violations and seek voluntary corrections. Persistent issues can result in seizures, injunctions, or criminal penalties under the Federal Food, Drug, and Cosmetic Act. [3]

Why did the FDA issue warning letters to dietary supplement companies for unsubstantiated stress and anxiety claims?
The FDA acted because phrases promising to reduce stress, relieve anxiety, or treat related symptoms qualify as disease claims. These turn ordinary supplements into unapproved drugs that have not undergone required safety and efficacy review. [1]